News for Solid Biosciences Inc. (SLDB)

On February 18, 2025, COMMODORE CAPITAL LP (Trades, Portfolio) made a significant move by acquiring 5,825,000 shares of Solid Biosciences Inc (NASDAQ: SLDB) at

On February 19, 2025, Bain Capital Life Sciences Investors, LLC (Trades, Portfolio) made a significant move by acquiring an additional 1,000,000 shares in Solid

On February 19, 2025, Perceptive Advisors LLC made a significant move by acquiring an additional 5,028,033 shares of Solid Biosciences Inc (SLDB). This transact

On February 19, 2025, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) made a significant move by acquiring an additional 3,659,374 shares of Solid Biosciences I

The S&P 500 futures have risen by 22 points, trading 0.4% higher. Nasdaq 100 futures are up 93 points, also trading 0.4% higher. Dow Jones Industrial Average fu

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. ( SLDB) (the ”œCompany” or ”œSolid”), a life sciences company developing pr

Solid Biosciences Inc. (SLDB) Tuesday reported positive initial data from the Phase 1/2 INSPIRE DUCHENNE study of its gene therapy product candidate SGT-003 for the treatment of Duchenne muscular dystrophy.

Solid Biosciences receives FDA Fast Track designation for gene therapy candidate SGT-212 for Friedreich’s Ataxia treatment.

- Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan

- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient

**media[516268]**

Solid Biosciences CFO Kevin Tan sells $15,849 in company stock

**media[510099]**

Solid Biosciences (SLDB) stock was launched by Truist with a Buy rating based on positive catalysts and attractive valuation. Read more here.

Seattle-based biotechnology company Sana Biotechnology, Inc. (SANA) is up over 227 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Solid Biosciences (SLDB) stock jumped 11% post-market on news the FDA had cleared an Investigational New Drug application for its gene therapy SGT-212 for Friedreich’s ataxia.

- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - - Dual rout

The exosome market is fueled by several significant factors, such as the rising incidence of chronic diseases, improvements in diagnostic methods, and...